What is Lucid Diagnostics's latest dividend and current dividend yield?

What guidance did Lucid Diagnostics's management provide for the next earnings period?

What is Lucid Diagnostics's gross profit margin?

Did Lucid Diagnostics beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Lucid Diagnostics year over year?

What is the market's earnings forecast for Lucid Diagnostics next quarter?

What factors drove the changes in Lucid Diagnostics's revenue and profit?

What were the key takeaways from Lucid Diagnostics’s earnings call?

- **Revenue Surge**: Q4 2025 test volume up 29% to 3,664, revenue $1.5 million (24% QoQ growth), driven by event-based testing efficiency.
- **VA Breakthrough**: Secured VA contract at Medicare rate, targeting 2-3 million high-risk veterans.
- **Medicare on Horizon**: Draft LCD imminent; 16% of Q4 claims Medicare, up 28% QoQ, with $2M+ backlogged collections.
- **Payer Wins**: UnitedHealthcare credentialing underway; first LBM policy expected soon.
- **Financial Health**: $34.7M cash, $11.1M quarterly burn, non-GAAP loss $0.43/year.

**【CEO Summary Section】**
- **EsoGuard Test Volume Growth**: Q4 2025 volume reached 3,664 tests, up 29% sequentially, exceeding the 2,500-3,000 target range. Revenue was $1.5 million, a 24% increase from Q3.
- **VA Contract Milestone**: Secured VA Federal Supply Schedule (FSS) contract at Medicare rate ($1,938), covering 9 million veterans with high esophageal disease risk.
- **Real-World Data Success**: 12,000-patient study showed 95% technical success for EsoCheck, completed in under 2 minutes, with 100% safety.
- **Reimbursement Progress**: Medicare LCD draft expected soon; UnitedHealthcare policy update enables de facto coverage, with credentialing underway.
- **EHR Integration**: Early-stage efforts to facilitate test ordering and result delivery, with potential Epic integration in the future.

**【CFO Financial Commentary】**
- **Cash Position**: $34.7 million at year-end, with quarterly burn rate of $11.1 million (excluding one-time expenses).
- **Revenue Recognition Challenges**: $9 million billable amount vs. $1.5 million recognized revenue due to collection probability analysis.
- **Operating Expenses**: Non-GAAP operating expenses increased 10% YoY to $48.7 million, driven by sales and market access expansion.
- **Convertible Debt Impact**: $2.4 million non-cash expense from convertible note mark-to-market adjustments.

**【Q&A Highlights】**
- **Volume Growth Drivers**: Team productivity and event-based testing efficiency, not yet VA-related. Sequential growth may signal new run rate.
- **UnitedHealthcare Strategy**: Credentialing for in-network contracting, leveraging EGD policy inclusion for de facto coverage.
- **Medicare Mix**: Medicare claims rose 28% QoQ to 16% of volume, targeting 40%+ of addressable population.
- **Sales Team Reallocation**: Shifting focus to Medicare and VA without increasing headcount, balancing event-based and traditional engagement.
- **LBM Progress**: First positive LBM policy expected soon, aligning with Medicare guidelines for broader coverage.

Lucid Diagnostics Inc.(LUCD)-20260326-2025 Q4 Earnings call transcript

- **Medicare Milestone**: Unanimous CAC support signals imminent draft LCD, with retroactive claims possible within 12 months of approval.
- **Financial Strength**: $47 million cash runway post-$27 million offering, enabling Medicare-focused commercial acceleration.
- **Commercial Momentum**: 2,841 tests/Q3, targeting 50% Medicare-eligible patients, with initial successes in shifting volume mix.
- **Cost Efficiency**: Stable $200/test variable costs, with automation/AI opportunities for future savings.
- **Strategic Initiatives**: Firefighter Summit and NIH study expand reach, while UnitedHealthcare guideline inclusion drives commercial payer engagement.

**【CEO Summary Section】**
- **EsoGuard Performance**: Q3 2025 saw 2,841 tests conducted, generating $1.2 million in revenue, consistent with Q2 2025. The company maintains a target of 2,500-3,000 tests per quarter to engage commercial payers.
- **Medicare Progress**: The September 2025 Contract Advisory Committee (CAC) meeting resulted in strong consensus for Medicare coverage. A draft Local Coverage Determination (LCD) is anticipated, with a 45-day public comment period expected to follow.
- **Commercial Expansion**: The company strengthened its market access team and secured a $27 million public offering, extending runway through 2026. Efforts to target Medicare-eligible patients (50% of the 30 million target population) are underway, with initial successes in shifting test volume mix.
- **Firefighter Initiative**: The first Firefighter Esophageal Cancer Prevention Summit was held, aiming to expand contracted testing events with fire departments, a high-risk population for esophageal cancer.

**【CFO Financial Commentary】**
- **Financial Health**: Cash balance stood at $47.3 million as of Q3 2025, supported by a $27 million public offering. Quarterly burn rate was $10.3 million, slightly below the trailing 4-quarter average of $10.5 million.
- **Revenue Recognition**: Due to reimbursement uncertainties, 17% of billed tests ($7.1 million) were recognized as revenue. Medicare approval could enable retroactive claims dating back 12 months.
- **Cost Structure**: Variable costs per test remain stable at ~$200, with no significant inflationary pressures expected.

**【Q&A Highlights】**
- **Medicare Timeline**: The company expects a draft LCD by year-end 2025, with final coverage likely following the public comment period. Discussions with commercial payers are accelerating, leveraging updated guidelines linking EsoGuard to endoscopy coverage.
- **Commercial Payer Engagement**: UnitedHealthcare has included EsoGuard in its endoscopy guidelines, facilitating direct contracting discussions. The team is targeting ~50% of tests from Medicare-eligible patients, up from the current 10-15%.
- **Cost Efficiency**: Variable costs remain stable, with automation and AI opportunities to reduce lab expenses in the future.
- **NIH Study**: The asymptomatic GERD study is enrolling well, with potential to expand the addressable population beyond the current 30 million target. Results are not expected to impact near-term commercial efforts.

Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue up 40% sequentially to $1.2M, driven by Hoag partnership and commercial pipeline.
- **Medicare Milestone**: Upcoming CAC meeting (Sept 4) with multi-MAC collaboration; draft LCD expected within 3 months.
- **Commercial Expansion**: First commercial coverage policy with Highmark; engaging regional Blue Cross plans and fire departments.
- **Financial Strength**: $31.1M cash post-$16M financing; 90% contribution margin at Medicare rate.
- **Pipeline Potential**: 30M+ addressable patients, with 40-50% Medicare-eligible. NIH-funded study could expand market to GERD-symptom-negative patients.

**【CEO Summary Section】**
- **Q2 2025 Performance**: Test volume reached 2,756 (within target range of 2,500-3,000), with revenue of $1.2 million, a 40% sequential increase. 
- **Strategic Milestones**: 
  - Launched comprehensive EsoGuard program with Hoag Health System, involving 200+ primary care physicians and concierge medicine.
  - Secured first commercial coverage policy with Highmark Blue Cross Blue Shield in Upstate New York.
  - Published pilot study in *American Journal of Gastroenterology* showing EsoGuard's effectiveness in GERD-symptom-negative patients (8.4% prevalence).
- **Medicare Progress**: Upcoming MolDX Contractor Advisory Committee (CAC) meeting on September 4, 2025, with multi-jurisdictional MACs. Positive outcome expected to lead to draft Local Coverage Determination (LCD) and final policy within 3-6 months.
- **Commercial Pipeline**: Robust pipeline with fire departments, municipalities, and concierge medicine practices. Engaging regional Blue Cross Blue Shield plans and leveraging NIH-funded 5-year study ($8M grant).

**【CFO Financial Commentary】**
- **Balance Sheet**: $31.1M cash at end of Q2, with $16.1M net proceeds from public offering extending runway to 2026.
- **Revenue Recognition**: $1.2M recognized (17% of $6.9M billed), with 40% claims denied for medical necessity or prior authorization. Medicare coverage could unlock 40-50% of addressable patient population.
- **Operating Expenses**: Non-GAAP OpEx $11.1M (flat vs. prior quarters), with 90% contribution margin per test at Medicare rate ($1,938).
- **Financial Health**: Non-GAAP net loss of $9.9M (better than trailing 4Q average of $10.5M), with shares outstanding ~108.5M.

**【Q&A Key Highlights】**
- **Medicare Timeline**: Draft LCD expected post-CAC meeting, final policy by early 2026. Backlog of 12 months' claims eligible for retroactive payment.
- **Commercial Strategy**: Targeting regional Blue Cross plans and leveraging biomarker legislation (23+ states). Hoag partnership model replicable across health systems.
- **Capacity & Scaling**: Lab has 5x current capacity, manufacturing scalable with minimal capital. Contribution margin ~70% at scale.
- **Burn Rate Management**: Q2 burn $10.3M (slightly below 4Q average of $10.5M). ATM and underwritten offering provide optionality.


Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript

- **Q4 Test Volume Record**: 4,000 tests, exceeding 2,500-3,000 target, signaling strong demand and scalability.
- **First Commercial Coverage**: Highmark Blue Cross Blue Shield sets precedent for 30 million Medicare patients, with Q2 Medicare decision looming.
- **Clinical Validation**: NCCN guidelines inclusion and five peer-reviewed studies validate EsoGuard as essential screening tool.
- **Market Expansion**: NIH grant targets 60 million non-GERD patients, with pilot data showing 7-8% precancer prevalence.
- **Financial Resilience**: $37M cash post-RDO, with plans to halve burn rate via cash-pay and Medicare claims submissions.

**【CEO Summary Section】**
- **Record Q4 Test Volume**: Achieved 4,000 tests, surpassing the 2,500-3,000 quarterly target, reflecting strong demand and operational efficiency.
- **Revenue Growth Momentum**: Q4 revenue of $1.2 million, consistent with prior quarters, driven by traditional claims and emerging cash-pay channels.
- **Reimbursement Breakthroughs**: Secured first commercial insurance coverage with Highmark and expanded clinical guidelines inclusion in NCCM, setting precedents for broader payer engagement.
- **Clinical Evidence Expansion**: Published five peer-reviewed studies, including CLUE and ENVET-BE, solidifying EsoGuard's role as a triage tool for esophageal cancer screening.
- **Market Expansion via NIH Grant**: $8M NIH funding to study EsoGuard in non-GERD patients, potentially doubling the addressable market to 60 million patients.

**【CFO Financial Commentary】**
- **Strengthened Balance Sheet**: $22.4M cash at year-end, supplemented by a $15M registered direct offering, extending runway to 2026.
- **Burn Rate Management**: Q4 burn of $10.1M, down from $11M average, with plans to reduce further via cash-pay programs and Medicare coverage.
- **Revenue Recognition Dynamics**: GAAP revenue reflects collection probability, while contracted cash-pay tests enable upfront recognition, improving cash flow visibility.
- **Operational Efficiency**: Lab costs increased 8% sequentially due to record test volume, but one-time financing costs kept non-GAAP loss at $10.9M.

**【Q&A Highlights】**
- **Medicare Coverage Outlook**: Anticipate MolDX decision in Q2, with potential to flip 40% of target market to Medicare-covered patients, enabling rapid scaling.
- **Concierge Medicine Traction**: Signed 20 contracts in weeks, targeting high-margin cash-pay revenue starting Q3.
- **Burn Rate Reduction**: Expect 50% burn reduction by year-end via contracted revenue and Medicare claims backlog submission.
- **NIH Study Impact**: Pilot data shows 7-8% precancer prevalence in non-GERD patients, aligning with ACG guidelines for expanded screening.
- **Reimbursement Strategy**: Leverage biomarker legislation in 20 states and direct employer contracts to bypass traditional payer delays.

Actual	-0.23	-0.41	-0.28	-0.33	-0.24	-0.23	-0.22	-1.33	-0.99	-0.2	-0.2	-0.19	-0.16	-0.1	-0.1	-0.09
Forecast	-0.2595	-0.333	-0.3512	-0.33	-0.3252	-0.2825	-0.2375	-0.23	-0.24	-0.2	-0.206	-0.178	-0.148	-0.114	-0.095	-0.092
Surprise	+11.37%	-23.12%	+20.27%	0.00%	+26.20%	+18.58%	+7.37%	-478.26%	-312.50%	0.00%	+2.91%	-6.74%	-8.11%	+12.28%	-5.26%	+2.17%

LUCD

LUCD fundamentals

LUCD Q4 2025 Earnings

Earnings Call

You can ask Aime

LUCD

LUCD fundamentals

LUCD Q4 2025 Earnings

Earnings Call

LUCD Earnings Call Summary for Q4/20258:30 AM on Mar 26, 2026

LUCD Earnings Call Summary for Q3/20258:30 AM on Nov 12, 2025

LUCD Earnings Call Summary for Q2/20258:30 AM on Aug 13, 2025

LUCD Earnings Call Summary for Q1/20258:30 AM on May 14, 2025

LUCD Earnings Call Summary for Q4/20248:30 AM on Mar 24, 2025

You can ask Aime